RNA binding motif protein 15Genealiases: OTT · OTT1
Q-omics provides the consensus-scored RBM15 profile across patient tissues and cancer cell-line models. RBM15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM15 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RBM15 protein abundance shows 26,198 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where RBM15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM15 survival associations across molecular data types. RBM15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM15 RNA expression–survival associations across cancer types. High RBM15 expression shows unfavorable associations in ACC, LIHC, KIRP and LGG, but favorable associations in KIRC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM15 RNA expression.
This table summarizes RBM15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM15 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, STAD, LUSC and COAD. The HNSC box plot shows higher RBM15 RNA expression in tumor versus normal tissue (log2 FC = +0.739, t-test p < 0.001).
This table shows molecular features associated with RBM15 in patient tissues and cancer cell lines. In patient samples, RBM15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
